<DOC>
	<DOCNO>NCT02491463</DOCNO>
	<brief_summary>The purpose first time human ( FTiH ) study assess safety , reactogenicity immunogenicity 2 dos RSV investigational vaccine , administer intramuscularly accord 0 , 1 month schedule , healthy adult age 18 45 year .</brief_summary>
	<brief_title>A Study Assess Safety , Reactogenicity Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' RSV Investigational Vaccine ( ChAd155-RSV ) ( GSK3389245A ) Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol Written inform consent obtain subject prior perform study specific procedure A male female , include , 18 45 year age time first vaccination Healthy subject establish medical history clinical examination enter study Female subject nonchildbearing potential may enrol study Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product Use investigational nonregistered product study vaccine period start 30 day first dose study vaccine , plan use study period Chronic administration immunosuppressant immunemodifying drug within 6 month prior study vaccination , plan administration study period Planned administration/administration vaccine foreseen study protocol period start 30 day first dose end 30 day last dose vaccine administration , exception license influenza vaccine may administer ≥ 15 day first dose ≥ 15 day last dose study vaccine Administration immunoglobulins and/or blood product period start 3 month first dose study vaccine plan administration study period Blood donation within 4 month prior study entry plan blood donation time study Previous vaccination RSV Previous vaccination recombinant simian human adenoviral vaccine Previous Bexsero vaccination Neisseria meningitidis serogroup B History current autoimmune disease Family history congenital hereditary immunodeficiency History reaction hypersensitivity likely exacerbate component study vaccine . History neurological disorder seizures History transient thrombocytopenia neurological complication follow prior vaccination Hypersensitivity latex Hypersensitivity Bexsero 's active substance excipients Allergic reaction kanamycin Any medical condition judgment investigator would make intramuscular injection unsafe Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Acute disease and/or fever time enrolment Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test Malignancy within previous 5 year lymphoproliferative disorder Any clinically significant ≥ Grade 2 haematological laboratory abnormality Body mass index &gt; 40 kg/m2 Current alcohol and/or drug abuse Pregnant lactate female Any condition investigator judge may interfere study procedure finding Planned move location prohibit participate trial study end</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Reactogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Respiratory syncytial virus ( RSV )</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>